Organon & Co. (NYSE:OGN) Rating Increased to Strong Sell at Barclays

Barclays upgraded shares of Organon & Co. (NYSE:OGN) to a strong sell rating in a research report report published on Monday morning,Zacks.com reports.

Several other brokerages also recently commented on OGN. Piper Sandler downgraded Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a research note on Monday, October 27th. JPMorgan Chase & Co. lowered their target price on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. Finally, Morgan Stanley cut their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and a consensus target price of $8.38.

Organon & Co. Stock Up 1.1%

OGN stock traded up $0.08 on Monday, reaching $7.03. 266,480 shares of the company traded hands, compared to its average volume of 4,737,436. The firm has a fifty day simple moving average of $8.15 and a 200-day simple moving average of $9.20. The company has a market cap of $1.83 billion, a P/E ratio of 3.66, a price-to-earnings-growth ratio of 1.56 and a beta of 0.57. Organon & Co. has a one year low of $6.18 and a one year high of $17.23. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.

Organon & Co. (NYSE:OGN) last released its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same period in the prior year, the firm posted $1.38 earnings per share. Research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is presently 4.17%.

Institutional Trading of Organon & Co.

Several institutional investors have recently made changes to their positions in the business. Hanson & Doremus Investment Management bought a new position in Organon & Co. in the 2nd quarter worth approximately $26,000. Hantz Financial Services Inc. grew its stake in Organon & Co. by 293.8% during the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock valued at $26,000 after acquiring an additional 1,995 shares in the last quarter. Foster Dykema Cabot & Partners LLC bought a new stake in Organon & Co. in the 3rd quarter valued at $29,000. Ransom Advisory Ltd purchased a new stake in Organon & Co. in the 1st quarter worth $32,000. Finally, SouthState Corp boosted its holdings in shares of Organon & Co. by 1,857.0% during the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.